A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas
Authors:
- Axel Le CesneACAxel Le Cesne
- Sara CrestaSCSara Cresta
- Robert G. MakiRMRobert G. Maki
- Jean Yves BlayJBJean Yves Blay
- Jaap VerweijJVJaap Verweij
- Andrés PovedaAPAndrés Poveda
- Paolo G. CasaliPCPaolo G. Casali
- Carme BalañaCarme Balaña
- Patrick SchöffskiPSPatrick Schöffski
- Federica GrossoFGFederica Grosso
- Pilar LardelliPLPilar Lardelli
- Antonio NietoANAntonio Nieto
- 1 November 2012
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 48 (16) , 3036-3044
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric studyEuropean Journal of Cancer, 2011
- Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasoneInvestigational New Drugs, 2010
- Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular abberationsEuropean Journal of Cancer, 2010
- Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different SchedulesJournal of Clinical Oncology, 2009
- Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)Journal of Clinical Oncology, 2009
- Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancerAnnals of Oncology, 2009
- Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution seriesAnnals of Oncology, 2009
- A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimensBritish Journal of Cancer, 2007
- A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancerBritish Journal of Cancer, 2006
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000